|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-8-15
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Repeated subcutaneous injections of a monoclonal antibody against the p40 subunit of interleukins 12 and 23, ustekinumab, were used to treat patients with relapsing-remitting multiple sclerosis (RRMS) to assess the drug's safety, efficacy, and pharmacokinetics.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1474-4422
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
796-804
|
|
pubmed:dateRevised |
2011-7-29
|
|
pubmed:meshHeading |
pubmed-meshheading:18703004-Adolescent,
pubmed-meshheading:18703004-Adult,
pubmed-meshheading:18703004-Aged,
pubmed-meshheading:18703004-Antibodies, Monoclonal,
pubmed-meshheading:18703004-Dose-Response Relationship, Drug,
pubmed-meshheading:18703004-Double-Blind Method,
pubmed-meshheading:18703004-Drug Administration Schedule,
pubmed-meshheading:18703004-Female,
pubmed-meshheading:18703004-Humans,
pubmed-meshheading:18703004-Immunocompromised Host,
pubmed-meshheading:18703004-Immunosuppression,
pubmed-meshheading:18703004-Injections, Subcutaneous,
pubmed-meshheading:18703004-Interleukin-12,
pubmed-meshheading:18703004-Interleukin-23,
pubmed-meshheading:18703004-Male,
pubmed-meshheading:18703004-Middle Aged,
pubmed-meshheading:18703004-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:18703004-Neoplasms,
pubmed-meshheading:18703004-Opportunistic Infections,
pubmed-meshheading:18703004-Placebos,
pubmed-meshheading:18703004-Protein Subunits,
pubmed-meshheading:18703004-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
|
|
pubmed:affiliation |
Department of Neurology, Holtom-Garrett Programme in Neuroimmunology, University of Michigan, Ann Arbor, MI 48109-2200, USA. bmsegal@med.umich.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
